To include your compound in the COVID-19 Resource Center, submit it here.

Taunton-Rigby takes on a turnaround

Cambridge Biotech Corp. took its first step toward turning around the company, which went into Chapter 11 in July 1994, appointing Alison Taunton-Rigby president and CEO.

Taunton-Rigby told BioCentury she was attracted to Cambridge Biotech by its strong technology base, the fact that it already has products on the

Read the full 480 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers